XOMA Acquires Mural Oncology for $2.035 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: Globenewswire
- Acquisition Completed: XOMA Royalty has successfully completed its acquisition of Mural Oncology, with shareholders receiving $2.035 per share in cash as sanctioned by the Irish High Court, marking a significant expansion in XOMA's biotechnology portfolio.
- Shareholder Approval: The acquisition was approved at a special meeting on October 24, 2025, reflecting strong shareholder support for XOMA's strategic direction and enhancing its market position in the biotech sector.
- Transaction Effective: The acquisition became effective on December 5, 2025, with Mural's shares ceasing to trade on Nasdaq, indicating XOMA's efforts to integrate its assets for optimized operations and strategic growth.
- Legal Support: XOMA received legal assistance from Gibson, Dunn & Crutcher LLP and Mason Hayes & Curran LLP during the transaction, ensuring compliance and smooth execution, which further bolsters its credibility in the industry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
